BIOGEN INC. 8-K

What Happened

• Biogen Inc. filed an 8‑K on February 11, 2026, reporting that Caroline Dorsa, Chair of Biogen’s Board, announced she will not stand for re‑election at the 2026 Annual Meeting of Stockholders. The filing states her decision is not related to any disagreement with the Board or the Company on operations, policies or practices.
• On the same date the Board elected Dr. Maria C. Friere to serve as Chair of the Board, effective after the 2026 Annual Meeting.

Key Details

• Filing date: February 11, 2026 (Form 8‑K; Items 5.02 & 8.01).
• Caroline Dorsa: current Board Chair; will not seek re‑election at the 2026 Annual Meeting.
• Board action: Dr. Maria C. Friere elected Chair, effective after the Annual Meeting.
• The departure was explicitly stated as not due to any disagreement with the Company or Board.

Why It Matters

• Board leadership changes are material governance events that can influence investor confidence and oversight of strategy and management.
• This filing does not report any operational or executive departures beyond the chair role, and it notes the decision was not due to disagreements, which may reduce concern about governance conflicts.
• Investors should watch proxy materials and any subsequent Company communications for additional context on board composition and any related governance changes.